NeuroSearch A/S' 2008 announcement will be on the agenda of a board meeting
scheduled for 4 March 2009 and will be released immediately hereafter.

On the same day, a teleconference will be held at 3 pm Copenhagen time (2 pm
London time, 9 am New York time, in which Flemming Pedersen, CEO, Anita
Milland, Vice President, CFO and Hanne Leth Hillman, Vice President, Director
of IR & Corporate Communications, will present the 2008 announcement and answer
questions. The telephone conference will be conducted in English and the
telephone number is +44 (0)20 7162 0077. The corresponding PowerPoint
presentation will be available via www.neurosearch.com.


Contact person:
Hanne Leth Hillman, Vice President, Director of IR & Corporate Communications,
telephone: +45 4460 8212 or +45 4017 5103



NeuroSearch (NEUR) is a Scandinavian biopharmaceutical company listed on Nasdaq
OMX Copenhagen. The company's core business covers the development of novel
drugs, based on a broad and well-established drug discovery platform focusing
on ion channels and CNS disorders. A substantial share of NeuroSearch's
activities is partner financed through an alliance with Eli Lilly and Company
and collaborations with GlaxoSmithKline (GSK), Abbott and Astellas. The drug
pipeline comprises 10 clinical (Phase I-III) development programmes: ACR16 for
Huntington's disease (Phase III), tesofensine for obesity and type 2 diabetes
(Phase III ready), ABT-894 for ADHD (Phase II) in partnership with Abbott,
ACR16 for schizophrenia (Phase I) in partnership with Astellas, ACR325 for
Parkinson's disease (Phase II in preparation) and bipolar disorder (Phase II in
preparation), ABT-107 and ABT-560 for the treatment of various CNS disorders -
both (Phase I) in collaboration with Abbott, ACR343 for Parkinson's disease
(Phase I) and NSD-788 for anxiety/depression (Phase I). In addition,
NeuroSearch has a broad portfolio of preclinical drug candidates and holds
equity interests in several biotech companies.

presse.02-09 - release date of 2008 announcement- uk - final.pdf